Literature DB >> 4022479

Use of beta-methasone in management of preterm gestation with premature rupture of membranes.

G F Simpson, G M Harbert.   

Abstract

Use of corticosteroids in the management of rupture of the membranes in a preterm gestation was evaluated. Ninety-three mothers (105 infants) received beta-methasone, whereas 105 mothers (112 infants) did not. The incidence of significant neonatal respiratory complications was statistically higher for beta-methasone-treated (26.6%) compared with non-treated patients (11.1%) who delivered more than 48 hours after rupture of membranes. Neonatal septic complications also were significantly higher in treated (21.3%) than in nontreated (9.2%) patients delivered 48 hours after rupture of membranes. Maternal sepsis was not statistically different between the two groups. In the nonsteroid-treated patients, the incidence of significant respiratory distress syndrome was greater for those infants delivered within 48 hours (31.0%) than those delivered more than 48 hours (11.1%) from rupture of membranes. The data support conservative management and indicate that corticosteroid administration in a preterm gestation with rupture of membranes is not beneficial to the newborn.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4022479

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  3 in total

1.  Premature rupture of membranes.

Authors:  A Akierman; S Iwanicki
Journal:  Can Fam Physician       Date:  1988-09       Impact factor: 3.275

Review 2.  Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth.

Authors:  Devender Roberts; Julie Brown; Nancy Medley; Stuart R Dalziel
Journal:  Cochrane Database Syst Rev       Date:  2017-03-21

3.  Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth.

Authors:  Emma McGoldrick; Fiona Stewart; Roses Parker; Stuart R Dalziel
Journal:  Cochrane Database Syst Rev       Date:  2020-12-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.